Pharma Sector

Trump’s unpredictable trade moves: 100% tariffs on pharma came just 12 hours after US trade official said none planned

The new 100% tariff on any branded or patented pharmaceutical product will apply to all imports unless the company has already broken ground on building a manufacturing plant in the United States, Trump said.

Trump's 50% tariffs threaten Indian goods: Which export sectors could suffer the most | Explained

India, which exported over $120 billion worth of goods to the US last year, risks losing its competitive edge across sectors that have long thrived under relatively low US duties.

Indian pharma firms dread tariffs, but US may have the worst side effects

Trump’s tariff threats have sent shockwaves through Indian pharma stocks, but analysts argue the real casualty could be the US healthcare system. With India supplying nearly half of US generics, tariffs might hike drug prices and cause shortages—hurting US consumers more than Indian drugmakers.

Motilal Oswal predicts robust growth for Indian pharma, picks five stocks to ride the wave

Motilal Oswal Wealth Management identified Lupin, Mankind Pharma, Piramal Pharma, Ipca Labs, and Max Healthcare as its top picks to capitalise on the robust growth in the domestic healthcare sector.

India, Uzbekistan discuss ways to ensure quality, safety in pharma sector

Temirov stressed the importance of developing effective mechanisms to prevent the entry of low-quality and counterfeit drugs into Uzbekistan’s pharmaceutical market.

Govt looking to tweak regulatory norms for MedTech, pharma sectors: Niti's VK Paul

VK Paul said Medtech Mitra is a humble initiative launched by the Indian Council of Medical Research (ICMR), which will pave the way for many potential products in diagnostics.

Mankind Pharma down as Sikkim floods disrupt operations

In the past three months, the stock has risen over 2 percent against a 0.3 percent decline in the Sensex

US FDA to step up unannounced inspections on Indian pharma plants

India will be a dominant part of planning the resilience of supply chains, United States Food and Drug Administration (US FDA) Commissioner Robert M Califf said

Pharma deep dive: Not the time to buy hospitals, bullish on diagnostics, says Incred’s Khemka

Khemka also says there are many reasons unbranded generics won’t work in India.

Home and away: Indian pharma firms reap the best of both worlds in Q1 FY24

Improved pricing and competitive environment in the US and resilient sales in the domestic market aided an uptick in revenue. Easing raw material inflation and lower freight soothed margin pressure.

Indian pharma market continues to cool down in July on lag in acute therapies

A slow offtake in the acute season resulted in weaker sales within the segment, dragging overall sales growth in the domestic pharma market in July.

Here is why Trideep Bhattcharya is bullish on Pharma

The veteran market investor follows a bottom up approach and likes the sector due to its diverse nature.

Pipeline Check: Here are the blockbuster drugs lined up by Indian drugmakers for US launch

Cipla is rolling out plans to launch a generic of Advair while Lupin has got approval for Spiriva